You searched for side effects - Page 81 of 311 - Medivizor
Navigation Menu

Long-term outcomes of the combination of ibrutinib, bendamustine and rituximab in relapsed/unresponsive CLL/SLL

Long-term outcomes of the combination of ibrutinib, bendamustine and rituximab in relapsed/unresponsive CLL/SLL

Posted by on Sep 24, 2020 in Non-Hodgkin lymphoma | 0 comments

In a nutshell This study aimed to investigate the long-term effectiveness of the combination of ibrutinib, bendamustine, and rituximab in relapsed/unresponsive chronic lymphocytic leukemia/small lymphocytic lymphoma. This study concluded that this combination was safe and effective in the long-term in these patients.   Some background...

Read More

Long-term outcomes of the combination of ibrutinib, bendamustine and rituximab in relapsed/unresponsive CLL/SLL

Long-term outcomes of the combination of ibrutinib, bendamustine and rituximab in relapsed/unresponsive CLL/SLL

Posted by on Sep 24, 2020 in Leukemia | 0 comments

In a nutshell This study aimed to investigate the long-term effectiveness of the combination of ibrutinib, bendamustine, and rituximab in relapsed/unresponsive chronic lymphocytic leukemia/small lymphocytic lymphoma.  This study concluded that this combination was safe and effective in the long-term in these...

Read More

Can a combination of dabrafenib and trametinib improve relapse-free survival after removal of stage 3 melanoma?

Can a combination of dabrafenib and trametinib improve relapse-free survival after removal of stage 3 melanoma?

Posted by on Sep 24, 2020 in Melanoma | 0 comments

In a nutshell This study investigated the long-term effectiveness and risks of the combination of dabrafenib (Tafinlar) and trametinib (Mekinist) for patients with stage 3 melanoma after tumor removal. It showed that the combination of the two drugs can increase survival without return or spreading of cancer. Some...

Read More

Seeking patients with relapsed follicular lymphoma for dosing study of idelalisib

Seeking patients with relapsed follicular lymphoma for dosing study of idelalisib

Posted by on Sep 20, 2020 in Non-Hodgkin lymphoma | 0 comments

In a nutshell This study will evaluate the best dose of idelalisib (Zydelig) for patients with relapsed follicular lymphoma (FL). The primary outcomes are overall response and side effects.  The details FL is a slow-growing cancer of B-cells, a type of white blood cell. Idelalisib is a medication that inhibits certain proteins involved in...

Read More

Looking for patients with advanced breast cancer to trial an experimental drug treatment.

Looking for patients with advanced breast cancer to trial an experimental drug treatment.

Posted by on Sep 20, 2020 in Breast cancer | 0 comments

In a nutshell This trial is aiming to examine the effectiveness of an experimental drug, AMXI-5001, in patients with advanced breast cancer. The main outcomes that are to be measured in this trial are side effects and the response to treatment. This trial is going to be carried out in California, Tennessee, and Florida, the United States. The...

Read More

Long-term outcomes of daratumumab, bortezomib, and dexamethasone in previously treated patients with multiple myeloma.

Long-term outcomes of daratumumab, bortezomib, and dexamethasone in previously treated patients with multiple myeloma.

Posted by on Sep 20, 2020 in Multiple Myeloma | 0 comments

In a nutshell This trial was carried out to examine the long-term safety and effectiveness of daratumumab (Darzalex) plus bortezomib (Velcade) and dexamethasone (Dexasone) in patients with previously treated multiple myeloma (MM). The authors concluded that after 3-years this treatment maintained benefit and...

Read More

The impact of G-CSF on brentuximab vedotin plus chemotherapy in treating newly diagnosed advanced Hodgkin lymphoma

The impact of G-CSF on brentuximab vedotin plus chemotherapy in treating newly diagnosed advanced Hodgkin lymphoma

Posted by on Sep 20, 2020 in Hodgkin's lymphoma | 0 comments

In a nutshell The study evaluated the impact of granulocyte-colony stimulating factor (G-CSF; Neupogen) on the outcomes of brentuximab-vedotin (BV; Adcetris) plus chemotherapy in newly diagnosed patients with stage-III/IV Hodgkin lymphoma (HL). The authors found that G-CSF improved the safety and efficacy outcomes of the combination therapy in such...

Read More

Evaluating the safety and effectiveness of polyethylene glycol loxenatide in patients with T2D

Evaluating the safety and effectiveness of polyethylene glycol loxenatide in patients with T2D

Posted by on Sep 20, 2020 in Diabetes mellitus | 0 comments

In a nutshell This study examined the effectiveness and risks of polyethylene glycol loxenatide (PEX168) as an add-on to metformin (Glucophage) therapy in patients with type 2 diabetes (T2D). It found that PEX168 is safe and works effectively in improving the blood sugar levels in these patients. Some background T2D is a...

Read More

Evaluating haploidentical stem cell transplantation for advanced lymphoma

Evaluating haploidentical stem cell transplantation for advanced lymphoma

Posted by on Sep 20, 2020 in Non-Hodgkin lymphoma | 0 comments

In a nutshell This study looked at the effect of a gentler stem cell transplant (SCT) from a partially matched donor for patients with advanced lymphoma. It found that haploidentical SCT is an effective treatment option for these patients. Some background Lymphomas are a group of cancers of white blood cells within the lymph nodes. Common types...

Read More

Evaluating haploidentical stem cell transplantation for advanced lymphoma

Evaluating haploidentical stem cell transplantation for advanced lymphoma

Posted by on Sep 20, 2020 in Hodgkin's lymphoma | 0 comments

In a nutshell This study looked at the effect of a gentler stem cell transplant (SCT) from a partially matched donor for patients with advanced lymphoma. It found that haploidentical SCT is an effective treatment option for these patients. Some background Lymphomas are a group of cancers of white blood cells within the lymph nodes. Common types...

Read More

Repetitive transcranial magnetic stimulation improves the treatment outcomes of patients with Parkinson’s disease

Repetitive transcranial magnetic stimulation improves the treatment outcomes of patients with Parkinson’s disease

Posted by on Sep 20, 2020 in Parkinson's Disease | 0 comments

In a nutshell This study investigated the effectiveness of repetitive transcranial magnetic stimulation (RTMS) in the treatment of patients with Parkinson's disease (PD). Researchers suggested that RTMS improves walking ability in these patients. Some background PD affects brain cells, which are responsible for controlling body functions. This...

Read More